Cervomed Inc (CRVO) Stock Price, Quote & News

Company Profile

CervoMed Inc., a a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurologic...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 744 4400

Website: www.cervomed.com

Address:

20 Park Plaza, Suite 424, Boston, United States

BPler Feb. 13 at 8:38 AM

$CRVO And with next earnings call we will probably also get an update on financing. I hope they aim for Revenue Interest Financing (RIF), as on October 28, 2025, CervoMed CEO John Alam, M.D., explicitly stated that the company is exploring external growth opportunities. "David's deep industry knowledge and proven track record supporting successful pipeline and commercial development, partnering, and M&A will be invaluable as we progress our planned Phase 3 program in DLB and evaluate strategic and business development initiatives."

1 · Reply

BPler Feb. 13 at 8:36 AM

$CRVO New positions reported yesterday in F13: 14.330 Shares - Hrt Financial Lp 11.076 Shares - Jane Street Group, Llc 13.951 Shares - Dimensional Fund Advisors Lp $BLK Blackrock Inc. confirmed they still have around 50.000 shares as well. https://fintel.io/de/so/us/crvo

0 · Reply

Messerschmittbf109 Feb. 12 at 8:33 PM

$CRVO $MS I laugh 😂

0 · Reply

Messerschmittbf109 Feb. 12 at 4:50 PM

$CRVO laundry machine… for sure Months of silence after just a pump and dump situation Similar China stock

0 · Reply

Messerschmittbf109 Feb. 12 at 4:20 PM

$CRVO these are parasites Bad people

0 · Reply

Scorpole Feb. 12 at 4:05 PM

$CRVO For 2 months ago the offering price could have been $4,50. Today $2. In 2 months $1.

3 · Reply

CWL123 Feb. 12 at 3:14 PM

$CRVO yikes d

1 · Reply

BPler Feb. 11 at 9:53 PM

$MS $CRVO This makes Morgan Stanley a benefical owner When a large entity owns >5%, it usually helps the stock in two ways: Validation: It acts as a "seal of approval." If a major fund like Vanguard or a specialized biotech VC owns 8% of a small stock like Cervomed (CRVO), other investors assume they’ve done deep "due diligence" that a regular person can't do. Reduced "Float": Since that 5%+ block is being held long-term, those shares are effectively "off the market." This makes the remaining shares (the Float) scarcer, which can lead to higher price volatility if demand spikes.

0 · Reply

BPler Feb. 11 at 6:35 PM

$MS added more than 50.000 shares, owning now 473,681 shares in CervoMed Inc. $CRVO which equals to 5.4% of the company. CervoMed is a clinical-stage biotechnology company based in Boston, Massachusetts, that is developing neflamapimod, an oral drug intended to treat neurodegenerative diseases like Dementia with Lewy Bodies (DLB). As of February 2026, the company is preparing to initiate a global Phase 3 clinical trial for DLB in the second half of the year, following positive feedback and alignment with the FDA on their trial design. https://ir.cervomed.com/sec-filings/sec-filing/schedule-13g/0000895421-26-000035

1 · Reply

Messerschmittbf109 Feb. 11 at 5:35 PM

$CRVO …..

0 · Reply

CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies

Dec 2, 2025, 7:00 AM EST - 2 months ago

CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB)

Nov 24, 2025, 7:00 AM EST - 2 months ago

CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference

Oct 20, 2025, 8:00 AM EDT - 4 months ago

CervoMed to Present at the Emerging Growth Conference

Oct 8, 2025, 11:54 AM EDT - 4 months ago

CervoMed Drug Cut Dementia Progression Risk By 75% In Trial

Oct 8, 2025, 7:00 AM EDT - 4 months ago

CervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy Bodies

Oct 2, 2025, 8:00 AM EDT - 4 months ago

CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference

Sep 17, 2025, 7:30 AM EDT - 5 months ago

CervoMed Highlights Neflamapimod's Potential Benefits in Session on Dementia with Lewy Bodies at the 150th Annual American Neurology Association Conference

Sep 3, 2025, 8:00 AM EDT - 5 months ago

CervoMed to Participate in Upcoming Investor Conferences

Jul 28, 2025, 11:20 AM EDT - 7 months ago

CervoMed's Dementia Data Show Slowed Disease Progression

Jul 28, 2025, 7:00 AM EDT - 7 months ago

CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod's Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration

Jul 8, 2025, 7:00 AM EDT - 7 months ago

CervoMed Announces Late-Breaking Presentations at Alzheimer's Association® International Congress 2025

May 12, 2025, 8:00 AM EDT - 9 months ago

CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Mar 31, 2025, 2:34 PM EDT - 11 months ago

Biotech Stocks Q1 2025 Recap: Winners And Underperformers

CMRX CVS GERN LLY NVO SEPN

Mar 25, 2025, 8:00 AM EDT - 11 months ago

CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders (AP/PD™)

Mar 22, 2025, 2:55 AM EDT - 11 months ago

CervoMed: Extension Study Data In Dementia With Lewy Bodies Is Potentially Exciting, With Caveats

Mar 10, 2025, 4:05 PM EDT - 1 year ago

CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies

Jan 29, 2025, 8:00 AM EST - 1 year ago

CervoMed to Present at the 8th International Lewy Body Dementia Conference

Dec 12, 2024, 7:00 AM EST - 1 year ago

CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 10, 2024, 11:37 AM EST - 1 year ago

CervoMed's Dementia Candidate Fails In Mid-Stage Study, Stock Plummets

Dec 10, 2024, 10:10 AM EST - 1 year ago

CervoMed's stock craters 77% after failed trial of treatment for rare brain disease

Dec 10, 2024, 7:33 AM EST - 1 year ago

CervoMed's dementia drug fails to meet mid-stage trial goals

Dec 10, 2024, 7:00 AM EST - 1 year ago

CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies

Nov 27, 2024, 7:00 AM EST - 1 year ago

CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia

Nov 12, 2024, 7:00 AM EST - 1 year ago

CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Nov 8, 2024, 9:55 AM EST - 1 year ago

CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup

Nov 4, 2024, 8:00 AM EST - 1 year ago

CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)

Oct 29, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference

Oct 2, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference

Aug 22, 2024, 8:00 AM EDT - 1 year ago

CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy Bodies

Jul 30, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Participate in The Canaccord Genuity 44th Annual Growth Conference

Jul 17, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Participate in the Emerging Growth Conference

Jul 11, 2024, 8:51 AM EDT - 1 year ago

CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024

Jun 11, 2024, 8:00 AM EDT - 1 year ago

CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies

May 20, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Appoint William Elder as Chief Financial Officer

May 15, 2024, 8:00 AM EDT - 1 year ago

CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Apr 2, 2024, 2:59 AM EDT - 2 years ago

CervoMed: H2 2024 Data For DLB Program A Major Inflection Point

Apr 1, 2024, 8:00 AM EDT - 2 years ago

CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

Mar 28, 2024, 8:30 AM EDT - 2 years ago

CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors

Mar 5, 2024, 8:00 AM EST - 2 years ago

CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024

Feb 21, 2024, 8:00 AM EST - 2 years ago

CervoMed to Participate in the BIO CEO and Investor Conference

Feb 12, 2024, 8:00 AM EST - 2 years ago

CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies

Feb 7, 2024, 8:30 AM EST - 2 years ago

CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board

Feb 5, 2024, 8:00 AM EST - 2 years ago

CervoMed to Participate in the Emerging Growth Conference 67

Jan 5, 2024, 8:00 AM EST - 2 years ago

CervoMed to Participate in the Emerging Growth Conference 66

Nov 13, 2023, 7:00 AM EST - 2 years ago

CervoMed Reports Third Quarter 2023 Financial Results and Business Highlights

Oct 25, 2023, 2:50 PM EDT - 2 years ago

CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Learnings from Phase 2a Which Optimized the Design of the Phase 2b Clinical Study of Neflamapimod in Dementia with Lewy Bodies

Oct 24, 2023, 7:00 AM EDT - 2 years ago

CervoMed Announces Publications in Major Peer-Reviewed Journals That Inform on Potential of Neflamapimod as a Disease-Modifying Therapy for the Major Dementias

Oct 18, 2023, 7:00 AM EDT - 2 years ago

CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Phase 2b Neflamapimod Program for the Treatment of Patients with Dementia with Lewy Bodies

Oct 5, 2023, 7:00 AM EDT - 2 years ago

CervoMed to Present at the 2023 Roth Healthcare Opportunities Conference

BPler Feb. 13 at 8:38 AM

1 · Reply

BPler Feb. 13 at 8:36 AM

0 · Reply

Messerschmittbf109 Feb. 12 at 8:33 PM

$CRVO $MS I laugh 😂

0 · Reply

Messerschmittbf109 Feb. 12 at 4:50 PM

$CRVO laundry machine… for sure Months of silence after just a pump and dump situation Similar China stock

0 · Reply

Messerschmittbf109 Feb. 12 at 4:20 PM

$CRVO these are parasites Bad people

0 · Reply

Scorpole Feb. 12 at 4:05 PM

$CRVO For 2 months ago the offering price could have been $4,50. Today $2. In 2 months $1.

3 · Reply

CWL123 Feb. 12 at 3:14 PM

$CRVO yikes d

1 · Reply

BPler Feb. 11 at 9:53 PM

0 · Reply

BPler Feb. 11 at 6:35 PM

1 · Reply

Messerschmittbf109 Feb. 11 at 5:35 PM

$CRVO …..

0 · Reply

Messerschmittbf109 Feb. 11 at 4:54 PM

$CRVO bankr uptcy soon This fart is The house of scoundr els

0 · Reply

CWL123 Feb. 11 at 4:40 PM

$CRVO wow i thought maybe we were going to see a turn around but i guess that movement was covering and now back at the short from 5.5 under 4 on the horizon

0 · Reply

BPler Feb. 11 at 3:24 PM

$CRVO "Brookline Capital Management upgraded shares of CervoMed (NASDAQ:CRVO – Free Report) to a strong-buy rating in a report published on Tuesday morning,Zacks.com" Missed this last week, CervoMed is under the radar similar as $ALMS was https://www.defenseworld.net/2026/02/06/cervomed-nasdaqcrvo-upgraded-at-brookline-capital-management.html

0 · Reply

BPler Feb. 11 at 3:22 PM

$CRVO https://www.linkedin.com/pulse/mitogen-activated-protein-kinase-14-market-report-analyzing-xaqof/ "Neflamapimod operates similarly but is tailored for neurodegenerative diseases, presenting unique therapeutic opportunities. "

0 · Reply

BPler Feb. 11 at 11:18 AM

Maybe just for one day we can keep the small bleeding shorters from $CRVO and $EVH away, $MAT you can have them 😅 Thank you, and bless your heart Mattel🙏

0 · Reply

BPler Feb. 11 at 6:29 AM

$CRVO Bank of New York Mellon Corp bought a new position with 10.000 shares, reported yesterday in F13 https://fintel.io/so/us/crvo

0 · Reply

Lizardbronsen Feb. 11 at 1:46 AM

$CRVO

0 · Reply

Messerschmittbf109 Feb. 10 at 10:15 PM

$CRVO …..💩🙅🏻

0 · Reply

Pharoh42 Feb. 10 at 10:06 PM

$CRVO This pos is a curse to my portfolio

1 · Reply

Messerschmittbf109 Feb. 10 at 7:09 PM

$CRVO this is the business

0 · Reply

Messerschmittbf109 Feb. 10 at 7:08 PM

$CRVO in 5 years -96% Bananas stock 🍌

0 · Reply

Messerschmittbf109 Feb. 10 at 7:07 PM

$CRDF $CRVO And so the way for new minima is next The embarrassment is that they should leave here after the embarrassment they made given the capitalization and the lack of concreteness... instead they always get their nice salary

0 · Reply

Market Cap	44.41M
Revenue (ttm)	9.74M
Net Income (ttm)	-16.29M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-167.25%
Debt to Equity Ratio	0.00

Volume	92,500
Avg Vol	70,152
Day's Range	N/A - N/A
Shares Out	9.25M
Stochastic %K	10%
Beta	-0.82
Analysts	Strong Sell
Price Target	$22.43